Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA reports medical-technology developments tied to the Genio system, its patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea. Company news commonly covers financial and operating results, U.S. commercialization activity, regulatory status, manufacturing capacity, reimbursement references, investor conference participation, and the development and commercialization of OSA treatment alternatives.
Nyxoah also publishes regulated information for its Euronext Brussels and Nasdaq securities, including transparency notifications, shareholder-meeting materials, voting-right disclosures, and bond-related capital-structure notices.
Nyxoah (NASDAQ: NYXH) signed a Memorandum of Understanding with Sheikh Shakhbout Medical City on February 18, 2026 to expand access to Genio hypoglossal nerve stimulation therapy in the Middle East.
The MoU targets development of a high-volume implant program, a regional training hub for surgeons and sleep physicians, and exploration of clinical research linking OSA management to chronic and metabolic diseases.
Nyxoah (Nasdaq: NYXH) announced an investment to expand its Belgian manufacturing capacity on January 21, 2026. The company signed an agreement with LégiaPark to create a nearly 2,000 square meters facility in Wallonia that includes a scalable, state-of-the-art cleanroom developed with ABN Cleanroom Technology. The expansion is intended to support growing demand in the United States and international markets, strengthen manufacturing readiness, foster local job creation, and, the company said, help improve its gross margin profile.
Nyxoah (NASDAQ: NYXH) reported preliminary unaudited results for Q4 and full-year 2025 and gave Q1 2026 revenue guidance. Q4 2025 gross revenue is ~€6.3M and net revenue ~€5.7M, up ~348% versus Q4 2024. FY2025 gross revenue is ~€11.0M and net revenue ~€10.0M, up ~122% versus FY2024. Deferred revenue related to disposable patches is ~€0.6M in Q4 and ~€1.0M for FY2025. As of Dec 31, 2025 the company trained 145 surgeons, activated 57 U.S. accounts, and held ~€47.9M in cash, cash equivalents and financial assets. Nyxoah expects U.S. net revenue Q1 2026 to grow ~25% sequentially and international revenue to follow seasonal patterns. Results are preliminary and subject to revision ahead of the 2025 Form 20-F filing.
Nyxoah (Nasdaq: NYXH) received a transparency notification from BNP Paribas Asset Management on January 8, 2026, reporting that BNP Paribas Asset Management Europe SAS holds 1,409,791 voting rights, representing 3.28% of total voting rights as of December 31, 2025 (denominator: 43,026,460).
The crossing of the 3% threshold follows a merger on December 31, 2025 between BNP Paribas Asset Management Europe SAS and AXA Investment Managers SA; the parent holding chain includes BNP Paribas Asset Management Holding and BNP Paribas SA, with an exemption noted under the Royal Decree on disclosure of major shareholdings.
Nyxoah (NASDAQ: NYXH) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 15, 2026. The presentation begins at 12:00 PM PT. A live audio webcast will be available on the company's investor relations website at investors.nyxoah.com.
This presentation offers investors a chance to hear management's update on Nyxoah's neuromodulation therapy for obstructive sleep apnea and company strategy directly from executives.
Nyxoah (NASDAQ/Euronext: NYXH) issued the first tranche of convertible bonds on December 18, 2025, raising €22.5 million of a possible €45 million facility with Heights Capital Management.
The bonds carry a 6.5% annual interest rate, three-year maturity, quarterly amortisation starting Feb 18, 2026, and an initial conversion price of €5.00. An 8% subscription fee (€1.8M) was set off against the proceeds. Proceeds support US commercialization, clinical programs, R&D and general corporate purposes.
Second tranche conditions were not met as of Dec 16, 2025; the first tranche extends cash runway into Q3 2026.
Nyxoah (Nasdaq: NYXH) announced the commercial launch of its Genio bilateral neurostimulation system in the Netherlands on December 17, 2025.
First successful Genio implants were performed at OLVG West (Amsterdam) and Zuyderland Hospital (Heerlen). Management said the system offers bilateral nerve stimulation, no implanted battery, full-body 1.5T and 3T MRI compatibility, and an externally powered activation chip that enables upgrades. Nyxoah described the launch as a step in its European rollout and said early implants validate Genio as a long-term CPAP alternative for patients who cannot tolerate CPAP.
Nyxoah (NASDAQ/Euronext: NYXH) received two transparency notifications from Robert Taub and related BMI Estate disclosing changes in voting rights on November 27 and December 2, 2025.
As of November 20, 2025 the holding totaled 4,290,800 voting rights (9.97%). As of December 1, 2025 the holding rose to 4,360,800 voting rights (10.14%), consisting of 4,310,800 linked securities and 50,000 warrants. The notifications identify controlled undertakings including Robelga SRL and describe ownership chains.
Nyxoah (Nasdaq: NYXH) announced its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec 4, 2025.
The session is scheduled for 1:30 p.m. ET and will be available via a live audio webcast on the company investor relations site at investors.nyxoah.com. The presentation will cover recent corporate developments and provide management commentary to investors and analysts.
Nyxoah (Euronext Brussels & Nasdaq: NYXH) published its updated capital and voting-rights figures on November 20, 2025. Key figures: share capital €6,504,688.76; total securities carrying voting rights 43,026,460 (all ordinary shares); total voting rights (denominator) 43,026,460. The company also reported 3,258,819 rights to subscribe to voting securities not yet issued (these are granted subscription rights) and excluded 692,677 subscription rights that were issued but not yet granted.
This disclosure is provided in accordance with applicable large-shareholding disclosure rules.